A Novel Neurotrophic Drug for Cognitive Enhancement and Alzheimer's Disease

被引:102
|
作者
Chen, Qi [1 ]
Prior, Marguerite [1 ]
Dargusch, Richard [1 ]
Roberts, Amanda [4 ]
Riek, Roland [2 ,5 ]
Eichmann, Cedric [5 ]
Chiruta, Chandramouli [1 ]
Akaishi, Tatsuhiro [3 ]
Abe, Kazuho [3 ]
Maher, Pamela [1 ]
Schubert, David [1 ]
机构
[1] Salk Inst Biol Studies, Cellular Neurobiol Lab, La Jolla, CA 92037 USA
[2] Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA
[3] Musashino Univ, Pharmacol Lab, Pharmaceut Sci Res Inst, Nishitokyo, Tokyo, Japan
[4] Scripps Res Inst, La Jolla, CA 92037 USA
[5] ETH, Phys Chem Lab, Zurich, Switzerland
来源
PLOS ONE | 2011年 / 6卷 / 12期
基金
美国国家卫生研究院;
关键词
LONG-TERM POTENTIATION; AMYLOID-BETA-PROTEIN; MOUSE MODEL; HIPPOCAMPAL-LESIONS; LEARNING-DEFICITS; TRANSGENIC MOUSE; MEMORY DEFICITS; STRESS-RESPONSE; CNS DISORDERS; MICE LACKING;
D O I
10.1371/journal.pone.0027865
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Currently, the major drug discovery paradigm for neurodegenerative diseases is based upon high affinity ligands for single disease-specific targets. For Alzheimer's disease (AD), the focus is the amyloid beta peptide (A beta) that mediates familial Alzheimer's disease pathology. However, given that age is the greatest risk factor for AD, we explored an alternative drug discovery scheme that is based upon efficacy in multiple cell culture models of age-associated pathologies rather than exclusively amyloid metabolism. Using this approach, we identified an exceptionally potent, orally active, neurotrophic molecule that facilitates memory in normal rodents, and prevents the loss of synaptic proteins and cognitive decline in a transgenic AD mouse model.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] A novel drug target in Alzheimer's disease
    Bornebroek, M
    Kumar-Singh, S
    LANCET, 2004, 364 (9447): : 1738 - 1739
  • [2] Cognitive enhancement therapy for Alzheimer's disease - The way forward
    Parnetti, L
    Senin, U
    Mecocci, P
    DRUGS, 1997, 53 (05) : 752 - 768
  • [3] Targeting Neural Oscillations for Cognitive Enhancement in Alzheimer's Disease
    Palacino, Federica
    Manganotti, Paolo
    Benussi, Alberto
    MEDICINA-LITHUANIA, 2025, 61 (03):
  • [4] Disease modification vs. cognitive enhancement in Alzheimer's disease treatment
    Waldemar, G
    NEUROBIOLOGY OF AGING, 2004, 25 : S91 - S91
  • [5] Progress in novel cognitive enhancers for cognitive aging and Alzheimer's disease
    Shineman, Diana W.
    Carman, Aaron J.
    Dacks, Penny A.
    Lane, Rachel F.
    Fillit, Howard M.
    ALZHEIMERS RESEARCH & THERAPY, 2013, 5 (05):
  • [6] Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
    Diana W Shineman
    Aaron J Carman
    Penny A Dacks
    Rachel F Lane
    Howard M Fillit
    Alzheimer's Research & Therapy, 5
  • [7] Strategies for drug discovery for cognitive aging and Alzheimer's disease
    Fillit, HM
    O'Connell, AW
    Refolo, LM
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2002, 19 (1-2) : 1 - 3
  • [8] Strategies for drug discovery for cognitive aging and alzheimer’s disease
    Howard M. Fillit
    Alan W. O’Connell
    Lorenzo M. Refolo
    Journal of Molecular Neuroscience, 2002, 19 : 1 - 3
  • [9] NOVEL PROGRAMS IN DRUG DISCOVERY FOR ALZHEIMER'S DISEASE
    Fillit, Howard M.
    Lane, R. F.
    Shineman, D. W.
    NEUROBIOLOGY OF AGING, 2012, 33 : S9 - S9
  • [10] The challenges of drug discovery and drug development for cognitive aging and Alzheimer's disease
    Fillit, H
    O'Connell, A
    DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE, 2000, 2002, : 1 - 4